CVS Health Co. (NYSE:CVS) Shares Sold by Impax Asset Management Group plc

Impax Asset Management Group plc decreased its position in shares of CVS Health Co. (NYSE:CVS) by 4.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 440,979 shares of the pharmacy operator’s stock after selling 19,049 shares during the quarter. Impax Asset Management Group plc’s holdings in CVS Health were worth $19,796,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. AMF Tjanstepension AB raised its position in shares of CVS Health by 124.1% during the 3rd quarter. AMF Tjanstepension AB now owns 61,744 shares of the pharmacy operator’s stock valued at $3,882,000 after buying an additional 34,198 shares during the period. Allworth Financial LP raised its position in CVS Health by 10.7% in the third quarter. Allworth Financial LP now owns 17,613 shares of the pharmacy operator’s stock valued at $1,108,000 after purchasing an additional 1,706 shares during the period. DekaBank Deutsche Girozentrale lifted its stake in shares of CVS Health by 222.9% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 1,858,556 shares of the pharmacy operator’s stock valued at $113,855,000 after purchasing an additional 1,282,956 shares during the last quarter. Bristlecone Advisors LLC increased its position in shares of CVS Health by 4.0% during the 3rd quarter. Bristlecone Advisors LLC now owns 10,340 shares of the pharmacy operator’s stock worth $650,000 after purchasing an additional 395 shares during the last quarter. Finally, Insight Folios Inc increased its position in shares of CVS Health by 3.5% during the 3rd quarter. Insight Folios Inc now owns 8,250 shares of the pharmacy operator’s stock worth $519,000 after purchasing an additional 282 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Price Performance

Shares of CVS opened at $62.95 on Tuesday. The company has a current ratio of 0.81, a quick ratio of 0.60 and a debt-to-equity ratio of 0.80. The firm’s fifty day simple moving average is $52.72 and its 200-day simple moving average is $56.25. The firm has a market capitalization of $79.37 billion, a price-to-earnings ratio of 17.20, a PEG ratio of 0.98 and a beta of 0.61. CVS Health Co. has a twelve month low of $43.56 and a twelve month high of $80.75.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Equities analysts forecast that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were issued a $0.665 dividend. The ex-dividend date of this dividend was Thursday, January 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.23%. CVS Health’s dividend payout ratio is presently 72.68%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. UBS Group lowered their target price on shares of CVS Health from $62.00 to $59.00 and set a “neutral” rating for the company in a research note on Tuesday, February 11th. Wolfe Research lifted their target price on shares of CVS Health from 67.00 to 70.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Deutsche Bank Aktiengesellschaft raised CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price on the stock in a research report on Tuesday, December 3rd. Wells Fargo & Company lifted their price objective on CVS Health from $68.00 to $73.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Finally, Royal Bank of Canada decreased their target price on CVS Health from $68.00 to $58.00 and set an “outperform” rating on the stock in a research note on Friday, November 15th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.00.

Insider Buying and Selling

In other news, Director Michael F. Mahoney acquired 30,000 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the transaction, the director now directly owns 39,356 shares in the company, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.24% of the stock is currently owned by insiders.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.